Why is adrenaline (epinephrine) given at a lower dose in cardiac arrest due to local anesthesia toxicity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Why Lower-Dose Epinephrine in Local Anesthetic Systemic Toxicity (LAST) Cardiac Arrest

Standard-dose epinephrine (1 mg) should be reduced or avoided in cardiac arrest from local anesthetic toxicity because high-dose epinephrine may impair the effectiveness of lipid emulsion therapy and worsen outcomes, while lipid emulsion is the primary antidote that directly reverses the cardiotoxic effects of local anesthetics. 1

The Fundamental Problem with Standard Epinephrine Dosing

Local anesthetic systemic toxicity causes cardiac arrest through profound inhibition of voltage-gated sodium channels in cardiac cell membranes, creating a unique pathophysiology distinct from other cardiac arrest etiologies. 2 The cardiovascular collapse is particularly severe with bupivacaine, the most frequently implicated agent in LAST-related cardiac arrest. 2

Evidence Against High-Dose Epinephrine in LAST

Animal studies demonstrate that lipid emulsion therapy combined with high-dose epinephrine (0.1 mg/kg or 0.01-0.025 mg/kg) showed no additional benefit compared to lipid emulsion alone, suggesting that standard or high-dose epinephrine may be counterproductive. 1 Two controlled animal studies specifically found that lipid emulsion improved return of spontaneous circulation (ROSC) rates when compared with vasopressor therapy (vasopressin and epinephrine) in local anesthetic toxicity models. 1

The 2015 American Heart Association guidelines note that complex pharmacodynamic interactions exist between intravenous lipid emulsion and epinephrine during resuscitation, raising concerns about their combined use at standard doses. 1

The Lipid Emulsion Priority

Intravenous lipid emulsion is the primary treatment for LAST-induced cardiac arrest and should be administered immediately, using a 20% emulsion with an initial bolus of 1.5 mL/kg lean body mass over 1 minute, followed by an infusion of 0.25 mL/kg per minute for 30-60 minutes. 1 The bolus can be repeated once or twice for persistent cardiovascular collapse, with a maximum total dose of 10 mL/kg over the first hour. 1

All 21 published cases of lipid emulsion use for bupivacaine-induced LAST demonstrated clinical improvement after administration, and the majority (81/103) of all LAST cases treated with lipid emulsion reported clinical improvement such as ROSC, relief of hypotension, or resolution of dysrhythmia. 1

Practical Dosing Algorithm for LAST Cardiac Arrest

Initial Management

  • Immediately administer lipid emulsion as the first-line antidote (1.5 mL/kg bolus of 20% solution over 1 minute). 1
  • Continue high-quality CPR throughout resuscitation. 1

Epinephrine Dosing Strategy

  • If epinephrine is used, consider reduced doses (less than the standard 1 mg) or avoid it initially while prioritizing lipid emulsion therapy. 1
  • The 2010 International Consensus specifically notes that two animal studies showed lipid emulsion was superior to standard vasopressor therapy (including epinephrine) for ROSC in local anesthetic toxicity. 1

When Standard Epinephrine May Be Harmful

  • Avoid high-dose epinephrine entirely (doses of 0.1 mg/kg or higher showed no benefit when combined with lipid emulsion). 1
  • Standard-dose epinephrine may impair the lipid sequestration mechanism by which lipid emulsion works to reduce local anesthetic concentration in tissues. 1

Critical Pitfalls to Avoid

Don't Delay Lipid Emulsion

The most common error is treating LAST cardiac arrest like standard cardiac arrest with repeated epinephrine doses while delaying lipid emulsion administration. Lipid emulsion should be given early in suspected local anesthetic toxicity, particularly when cardiac arrest occurs. 2

Don't Use Standard ACLS Dosing Blindly

The 2010 guidelines explicitly warn about risks of routinely administering adrenaline to patients in whom cardiac arrest is provoked by or associated with cocaine and other sympathomimetic drugs, which share sodium channel blocking properties with local anesthetics. 1 This same caution applies to LAST.

Recognize the Unique Mechanism

Unlike standard cardiac arrest where epinephrine improves coronary and cerebral perfusion pressure, LAST creates a lipid-soluble drug toxicity that requires lipid sequestration as the primary antidote, not adrenergic stimulation. 1 The lipid emulsion creates a lipid compartment in serum that reduces the concentration of lipophilic local anesthetics in tissues while also increasing cardiac inotropy through other mechanisms. 1

Supporting Evidence from Other Toxicologic Emergencies

The pediatric guidelines specifically recommend not giving beta-adrenergic blockers for cocaine toxicity (Class III recommendation), recognizing that adrenergic manipulation in sodium channel blocker toxicity can be harmful. 1 This principle extends to local anesthetic toxicity, which also involves sodium channel blockade.

For tricyclic antidepressant overdose (another sodium channel blocker), guidelines note that epinephrine and norepinephrine are more effective than dopamine when vasopressors are needed, but the emphasis is on sodium bicarbonate as the primary antidote rather than high-dose vasopressors. 1

The Bottom Line for Clinical Practice

When cardiac arrest occurs from local anesthetic toxicity, immediately give lipid emulsion as the primary antidote, continue high-quality CPR, and use reduced-dose or no epinephrine initially, as standard-dose epinephrine may interfere with lipid emulsion efficacy and has not been shown to improve outcomes in this specific toxicologic emergency. 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Bupivacaine-Associated Cardiovascular Collapse

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.